Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION)

Cancer Insight

Status and phase: Active, not recruiting; Phase 1

Conditions: Metastatic Pancreatic Adenocarcinoma

Treatments: Drug: NG350A (Cohort C); Drug: Nab-paclitaxel (nP) (Cohort A, B and C); Drug: Gemcitabine (gem) (Cohort A, B and C); Drug: Ipilimumab (Cohort A, B and C); Drug: Nivolumab (Cohort A); Drug: Hydroxychloroquine (HCQ) (Cohort B)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04787991

PICI0044

Details and patient eligibility

About

This trial is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Full description

This is an open-label, non-randomized, exploratory platform trial designed to assess the safety and antitumor activity of immunotherapy, in combination with standard of care chemotherapy, in participants with mPDAC who have not received prior therapy. Where supportive mechanistic data are available, immunotherapy may also be combined with other treatment modalities (eg, radiation). Each cohort of this platform trial will test a different immunotherapy combination and consist of up to 2 stages: an initial stage (Stage 1) to evaluate safety, biomarkers, and/or clinical activity of the combination and an expanded cohort (Stage 2), when warranted, based on the safety, clinical activity, and/or biomarker results from Stage 1. The Sponsor intends to modify and/or add new combinations to the protocol as data emerge from scientific findings, in this and other trials.

This trial will be conducted in participants with histologically or cytologically documented diagnosis of mPDAC, with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, who have not received prior systemic therapy for their disease in the metastatic setting. Participants must have adequate organ and hematologic function and acceptable performance status. Participants must consent to tumor biopsies, including a pre-treatment (baseline) and on-treatment samples.

Enrollment: 45 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Core Inclusion Criteria

1. Participant has histologically or cytologically documented diagnosis of pancreatic adenocarcinoma with metastatic disease. Participants with locally advanced disease are not eligible.

   a. Participants with recurrent locally advanced disease are eligible, provided: i. the last dose of chemotherapy and/or radiotherapy occurred > 4 months prior to the first dose of study intervention, and; ii. no systemic or radiotherapy has been administered in the metastatic setting.

2. Participant must have measurable disease by RECIST v1.1.

3. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

4. A baseline tumor tissue sample is mandatory for enrollment. If archival tumor tissue is not available, then a fresh tumor biopsy must be provided.

5. Participant must be age 18 years or older.

6. Participant must have adequate organ function.

Core Exclusion Criteria

1. Participant must not have received any prior treatment, including chemotherapy, biological therapy, or targeted therapy for mPDAC, with the following exceptions and notes:

   1. Participants who have received prior neoadjuvant or adjuvant therapy for pancreatic adenocarcinoma are eligible if neoadjuvant and adjuvant therapy (including chemotherapy and/or radiotherapy) was completed more than 4 months before the start of study intervention.
   2. Prior surgical resection is permitted.
   3. Participants who have received treatment with any other enadenotucirev-based therapy or anti-CD40 antibody at any time are not eligible for the study (cohort C only).

2. Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.

3. Participants with an active, known or suspected autoimmune disease. Participants with: type I diabetes mellitus; hypothyroidism only requiring hormone replacement; a history of Hashimoto syndrome, within 3 years of the first dose of study intervention, which resolved to hypothyroidism alone; skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment; or conditions not expected to recur in the absence of an external trigger are permitted to enroll.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

45 participants in 3 patient groups

Cohort A: Nivolumab + Ipilimumab + nP/gem

Experimental group

Treatment:

Drug: Nivolumab (Cohort A)

Drug: Gemcitabine (gem) (Cohort A, B and C)

Drug: Ipilimumab (Cohort A, B and C)

Drug: Nab-paclitaxel (nP) (Cohort A, B and C)

Cohort B: Hydroxychloroquine + Ipilimumab + nP/gem

Experimental group

Treatment:

Drug: Hydroxychloroquine (HCQ) (Cohort B)

Drug: Gemcitabine (gem) (Cohort A, B and C)

Drug: Ipilimumab (Cohort A, B and C)

Drug: Nab-paclitaxel (nP) (Cohort A, B and C)

Cohort C: NG-350A + Ipilimumab + nP/gem

Experimental group

Treatment:

Drug: Gemcitabine (gem) (Cohort A, B and C)

Drug: Ipilimumab (Cohort A, B and C)

Drug: Nab-paclitaxel (nP) (Cohort A, B and C)

Drug: NG350A (Cohort C)